Dr. Juliane Bernholz is a seasoned CEO, cell biologist, and molecular geneticist with over 30 years of leadership experience in the pharmaceutical industry having worked and lived in the US and several countries across Europe. Currently, she serves as the CEO of AM-Pharma in Utrecht, where she has played a pivotal role in developing innovative treatments for rare and critical care diseases, including Hypophosphatasia and Acute Kidney Injury. 

Before her tenure at AM-Pharma, Dr. Bernholz held senior leadership positions in R&D and Business Development at renowned companies such as Johnson&Johnson, Sanofi, Novartis and Actelion Pharmaceuticals. Throughout her career, she has successfully led cross-functional teams, managed complex drug development programs, and driven strategic initiatives across small molecules, biologics, new modalities and cutting-edge therapies and has played a key role in bringing multiple therapies to market. Furthermore she has successfully negotiated, executed and chaired collaborations with industry partners  and academic institutions.

With a robust foundation in scientific research, having worked alongside Nobel laureates and earned a PhD in Cell Biology, Dr. Bernholz is passionate about harnessing scientific innovation to enhance patient outcomes. She has also completed executive leadership programs at Wharton and IMD, including a Board Diploma.

Dr. Bernholz is committed to fostering collaboration and driving growth in the global pharmaceutical sector. Outside of her professional endeavors, she enjoys exploring diverse cultures, immersing herself in nature, and engaging in outdoor activities such as swimming, tennis, hiking and skiing. She is a proud mother of two grown sons.